NCT03742895: Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations, BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with ER+ or PR+ breast cancer must have received & progressed on at least one endocrine therapy (adjuvant or metastatic); Only patients with tumors that express a homologous recombination repair mutation (HRRm), homologous recombination deficiency (HRD) mutation, or somatic (not inherited) BRCA 1/2 mutation are eligible
Exclusions: Patients with a BRCA+ germline (inherited) mutation; Patients who have not received an anthracycline & a taxane in either the neoadjuvant/adjuvant or metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑